Personalized Tuberculosis Treatment Recommendation System (PTTRS) version 1: A Precision-Medicine Based Application for Recommending Personalized Treatment to Tuberculosis Patients

Publication date: Jun 23, 2025

Tuberculosis is one of the leading causes of death in underdeveloped and developing countries. The limited access to detailed drug susceptibility testing, lack of knowledge of second-line anti-TB drugs in underdeveloped nations, insufficient adherence to drug dosages, and comorbidities challenge the management of drug-resistant TB. Further, the number of deaths due to TB is increasing with time due to reasons such as high levels of resistance mutation in TB strains, lack of on-time delivery of treatment, and lack of personalized medicine. Thus, we have developed a web-based application for aiding in the personalized treatment of TB patients based on their medical condition. The application takes geographical location, age, sex, medical and travel history, AMR report and associated medical conditions (AMCs) of the patient as input, and thereafter, outputs the list of drugs which are safe for the patient. The application also helps in knowing the possible side-effects of various drug combinations administered for TB. Additionally, the application also outputs the side-effects of combination of drugs for TB and for any AMC that the patient is suffering with. PTTRS can be accessed at https://pttrs-bblserver.streamlit.app/. Our polypharmacy side effect predictor can be used for any other disease as well. It can be accessed at https://psep-bblserver.streamlit.app/.

PDF

Concepts Keywords
Helpful Al
Pharmacogenomics Drug
Python_intro Drugs
Tuberculosis Generalized
Https
Medrxiv
Models
Org
Patient
Points
Preprint
Pttrs
Table
Treatment
Version

Semantics

Type Source Name
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease MESH causes of death
disease IDO drug susceptibility
disease IDO history
disease MESH death
drug DRUGBANK Medical air
disease IDO bacteria
disease MESH weight loss
disease MESH infections
disease MESH COVID 19 pandemic
disease IDO infectious agent
drug DRUGBANK Methionine
disease IDO pathogen
drug DRUGBANK Rifampicin
drug DRUGBANK Isoniazid
disease MESH treatment failure
disease MESH drug interactions
disease MESH morbidity
drug DRUGBANK Ciprofloxacin
drug DRUGBANK Amikacin
disease IDO susceptibility
disease IDO infection
disease MESH AIDS
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH MDR tuberculosis
disease MESH diabetes mellitus
disease MESH arthritis
drug DRUGBANK Pyrazinamide
disease MESH drug side effects
drug DRUGBANK Coenzyme M
disease MESH Asthma
pathway KEGG Asthma
disease IDO algorithm
drug DRUGBANK Flunarizine
disease MESH anomalies
drug DRUGBANK Isoxaflutole
drug DRUGBANK p-Phenylenediamine
disease IDO facility
drug DRUGBANK Gold
drug DRUGBANK MCC
disease MESH hernia
disease MESH Gait
disease MESH missed Abortion
drug DRUGBANK Apomorphine
disease MESH Abscess
disease MESH Sarcoma
disease MESH Carcinoma
disease MESH Malignant hypertension
disease MESH hematoma

Download Document

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *